{"Clinical Trial ID": "NCT00068601", "Intervention": ["INTERVENTION 1:", "Standard chemotherapy", "Patients only receive chemotherapy containing cyclophosphamide.", "Cyclophosphamide: part of the intended therapeutic regimen", "INTERVENTION 2:", "More Goserelin", "Patients receive gos\u00e9r\u00e9line subcutaneously once every 4 weeks from one week before the start of chemotherapy containing cyclophosphamide. Treatment continues until chemotherapy is completed in the absence of disease progression or unacceptable toxicity.", "Cyclophosphamide: part of the intended therapeutic regimen", "Goserelin acetate: administered subcutaneously"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer confirmed histologically", "Step I-IIIA", "An operational disease", "Invasive bilateral synchronous breast cancer is allowed provided that primary tumours are not diagnosed more than one month apart and both tumours are negative hormonal receptors.", "3 to 8 months of pre-operative or post-operative chemotherapy containing alkylants (anthracyclines or non-anthracyclines) should be provided, meeting 1 of the following criteria:", "Treatment with anthracycline at 3 months and 4 months", "6 to 8 months/courses based on anthracycline", "6 to 8 months/non-anthracycline course", "- Hormonal receptor status:", "Negative estrogen receiver", "Negative progesterone receptor", "CHARACTERISTICS OF PATIENTS:", "Age", "18 to 49", "Gender", "Women", "Status of menopause", "Premenopausal", "State of play", "- Zubrod 0-2", "Life expectancy", "Unspecified", "Haematopoietic", "Unspecified", "Hepatic", "Unspecified", "Renal", "Unspecified", "Other", "No pregnancy or breast-feeding", "Fertile patients should use effective contraception against barriers.", "No other prior cancer, except skin cancer of properly treated basal cells or squamous cells, or in situ cancer of which the patient has not been ill for at least 5 years after treatment with curative intent.", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Unspecified", "- Chemotherapy", "See Disease Characteristics", "No prior cytotoxic chemotherapy", "Endocrinotherapy", "No other concomitant hormonal treatment", "Radiotherapy", "- Concomitant radiotherapy in the breast, chest wall or lymph nodes is permitted", "Surgery", "See Disease Characteristics", "Other", "\u2022 Simultaneous participation in other therapeutic clinical trials, including SWOG-S0221, is permitted"], "Results": ["Performance measures:", "Premature ovarian failure rate at 2 years", "- Ovarian insufficiency at two years is defined as amenorrhoea (no menstrual bleeding) for the previous six months AND the presence of follicle-stimulating hormone (FSH) in the postmenopausal interval.", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Standard chemotherapy", "Description arm/group: Patients receive chemotherapy containing cyclophosphamide alone.", "Cyclophosphamide: part of the intended therapeutic regimen", "Total number of participants analysed: 69", "Type of measure: Number of participants", "Unit of measure: Participants 15 21.7%", "Results 2:", "Title of the arm/group: Chemotherapy More Goserelin", "Description arm/group: Patients receive gos\u00e9r\u00e9line subcutaneously once every 4 weeks from one week before the start of chemotherapy containing cyclophosphamide. Treatment continues until chemotherapy is completed in the absence of disease progression or unacceptable toxicity.", "Cyclophosphamide: part of the intended therapeutic regimen", "Goserelin acetate: administered subcutaneously", "Total number of participants analysed: 66", "Type of measure: Number of participants", "Unit of measure: Participants 5 7.6%"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/111 (0.00 per cent)", "Thrombosis/thrombosis/embolism 0/111 (0.00 %)", "Adverse Events 2:", "Total: 1/103 (0.97%)", "- Thrombosis/thrombosis/embolism 1/103 (0.97%)"]}